<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20130710013940N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-02-02</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of attachment training on the attachment of mother and son, and Shadkami</public_title>
      <acronym></acronym>
      <scientific_title>The effect of attachment training on maternal and fetal attachment and happiness of Unintended  pregnant women referring to selected hospitals   of Shiraz University of Medical Sciences 1396</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-02-14</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>84</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/33730</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: By simple sampling, the subjects referred to the two medical centers that are eligible, are randomly divided into intervention and control groups. In this study, the allocation of people to the two groups was done using the permutation block method
 Became In this method A represents the person receiving the intervention and B represents the individual in the group
The control is. Considering the quadruple block; the AABB code 0 reversal, to ABAB's permutation
Code 1, to ABBA Code 2, to BAAB Code 3, to BBAA Code 4 and to BABA Code 5 to 9.
Then use the random number table to select the starting point randomly, followed by 21
Consider the number as a row or column.
Given the order of the table numbers, to any number
We hit the corresponding permutation for it, for example, if the first three numbers of the random number table
1, 0 and 5, respectively. The order of receiving treatment by the first 12 people in two groups, respectively, was from left to
Right ABABAABBBABA will be. So finally choose 21 of the table of the way
Allocation of a total of 84 people will be identified in two groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>.</hc_freetext>
      <i_freetext>Intervention 1: 1. Intervention group Include pregnant mothers with a gestational age of at least 28 weeks in gestational age of at least 28 weeks divided into three groups of 15 and will be formed for each classroom group. The training sessions included in the intervention group include the importance of maternal and fetal attachment, maternal attachment outcomes And embryos during infancy, teaching how to develop mother and fetus attachment skills, teaching the effect of happiness on pregnancy, methods of creating happiness and its benefits for mother and baby, educating breastfeeding exclusively. Training sessions are 4 weeks and one week in a session. Before and after the intervention, maternal attachment questionnaire and happiness and general health were The researcher will be completed. Intervention 2: 2.Control group Includes mothers who are not interrogated by the researcher and are used by the routine care of the hospital.At the same time as the intervention group, the beginning of the study phase and after 4 weeks of training, the intervention group at the end of week 38 will be considered for the attachment of mother to fetus and happiness and general health of the control group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The whole data information after being unidentifiable is shared

When:
Start the access period 6 months after printing the results

To whom:
Researchers working in academic and academic institutions

Conditions:
To carry out more clinical trials and further advancement in this field

Where to obtain:
To the email address below fahime.fati91@gmail.com or to the Vice-Chancellor for Research in Shiraz University of Medical Sciences.

How to obtain:
Applying for yourself and your research work, the purpose of using the data is to indicate your contact number and address.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fahime Hasanzade</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>36 Zand streat</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7444135554</zip>
        <telephone>+98 71 5272 1655</telephone>
        <email>Akbarzadm@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>marzieh akbarzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>36 Ztand strea</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>71936-13119</zip>
        <telephone>+98 716474254</telephone>
        <email>Akbarzadm@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1- Women Without Pregnancy                                                           2. Failure to have mental disorders (psychosis, schizophrenia)    3. Ability to attend classes and complete the written consent form.                                                                                                    4. Earn a mental health score of less than 22                                                 5. Lack of participation in any kind of educational class including physiological delivery</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>participation in any kind of educational class including physiological delivery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>N/A</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>1. Intervention group Include pregnant mothers with a gestational age of at least 28 weeks in gestational age of at least 28 weeks divided into three groups of 15 and will be formed for each classroom group. The training sessions included in the intervention group include the importance of maternal and fetal attachment, maternal attachment outcomes And embryos during infancy, teaching how to develop mother and fetus attachment skills, teaching the effect of happiness on pregnancy, methods of creating happiness and its benefits for mother and baby, educating breastfeeding exclusively. Training sessions are 4 weeks and one week in a session. Before and after the intervention, maternal attachment questionnaire and happiness and general health were The researcher will be completed.</i_keyword>
      <i_keyword>2.Control group Includes mothers who are not interrogated by the researcher and are used by the routine care of the hospital.At the same time as the intervention group, the beginning of the study phase and after 4 weeks of training, the intervention group at the end of week 38 will be considered for the attachment of mother to fetus and happiness and general health of the control group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>1.The percentage of attachment – fetal attachment in wanted pregnancy. Timepoint: Before the intervention ، 2 weeks after the end of the training session. Method of measurement: Maternal Attachment Questionnaire.</prim_outcome>
      <prim_outcome>2.The percentage of attachment – fetal attachment in unwanted pregnancy. Timepoint: Before the intervention ، 2 weeks after the end of the training session. Method of measurement: Maternal Attachment Questionnaire.</prim_outcome>
      <prim_outcome>The percent of women's happiness in wanted pregnancy. Timepoint: Before the intervention ، 2 weeks after the end of the training session. Method of measurement: Oxford Happiness Inventory,.</prim_outcome>
      <prim_outcome>The percent of women's happiness in unwanted pregnancy. Timepoint: Before the intervention ، 2 weeks after the end of the training session. Method of measurement: Oxford Happiness Inventory,.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-04-29</approval_date>
        <contact_name>Ethics committee of Shiraz university of medical sciences</contact_name>
        <contact_address>36 Zand streat Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
